PubMed Health⌕ Search

PubMed · 14594576

Relapsing polychondritis.

Abstract

A 57-year-old man presented with a 2-year history of (1) recurrent swelling of the ears that spared his earlobes and (2) migratory arthralgias. A biopsy specimen of the ear showed a perichondrial infiltrate of lymphocytes, plasma cells, and a few neutrophils. There were acellular foci of underlying cartilage. Relapsing polychondritis is characterized by recurrent inflammation and eventual destruction of cartilaginous tissues, primarily affecting the ears, nose, respiratory tract, and eyes. The condition, which is associated with autoimmunity against type II collagen, has a chronic, relapsing-and-remitting course that can be life-threatening. Treatments include a variety of anti-inflammatory and anti-neutrophilic agents, and the prognosis is variable and depends on which organ systems are involved and the response to therapy.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Arash K Asadi. 2003. Relapsing polychondritis.. https://pubmed.ncbi.nlm.nih.gov/14594576/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus].

According to the NIH scheme, the "evidence based medicine" standard in the treatment of severe proliferative lupus-nephritis is cyclophosphamide in combination with steroids. Undesired effects, therapy resistance, and deficient long-term effects underscore the necessity for the development of alternative therapies for the treatment of organ involvement. Mycophenolate mofetil (MMF) possesses the potential to decisively improve the therapeutic possibilities for systemic lupus erythematosus (SLE). On the basis of the available data, MMF represents an alternative to the current standard therapies for severe lupus-nephritises and shows less toxicity. MMF is also effective in patients with other manifestations refractory to conventional therapy. Questions remain unanswered on the optimal dosage and possible reduction in cases of remission. In addition, the duration of maintenance therapy is unclear. Therefore, large, prospective, randomized clinical studies in the treatment of lupus-nephritis with a sufficiently long follow-up phase are underway.

Drug Therapy, Combination↗